Emma Harvey is global head of medical affairs at F2G Ltd, a UK and Austria based biotech where she is responsible for the global medical and commercial strategies for a novel antifungal drug for serious systemic infections, in clinical development.
Novartis announced today (October 2) that it is excited about positive top-line results from its study into iptacopan, a drug to treat IgA nephropathy (IgAN).
A new approach to discovering targets for Alzheimer’s and other neurodegenerative diseases has been presented by Insilico Medicine with the University of Cambridge, UK.
The Japanese firm Astellas Pharma will apply for planning permission to construct a drug manufacturing facility in Tralee, Co. Kerry, Ireland worth around €330 million ($352 million).
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for Pombliti + Opfolda, a two-component therapy to treat Pompe disease.
OSP discussed going beyond industry sponsors and how to support both patients and centers through clincal trial design with Erin Leckrone, senior director, clinical trials and Kathleen Kane, senior manager, clinical operations, at Be The Match BioTherapies....
Calliditas Therapeutics AB’s phase 3 study looking at a cure for a kidney disease called IgA nephropathy (IgAN) has met its primary endpoint and the full data has been published in The Lancet.
The first patient has been enrolled in a phase 3 clinical trial of leniolsib a treatment for a rare inherited condition affecting how the immune system works.
The National Health Service (NHS) research ethics committee has approved a non-cancer chronic pain clinical trial being rolled out by private health clinic LVL Health.
This year’s CPHI South East Asia is expecting a surge in international partnering with organizers expecting a record attendance of 8,000 visitors including a significant number from overseas – doubling last year’s figures.
Drugs like Annovis Bio’s buntanetap and prasinezumab have the potential to “revolutionize the treatment of Parkinson’s Disease” says analytics company, GlobalData, an analytics company, but it is a complex road ahead.
The world’s first anti-fibrotic small molecule inhibitor, discovered and designed by generative artificial intelligence (AI) has completed the first patient dose in a phase 2 clinical trial.
The Japanese company Shionogi has taken over the US biotech Qpex Biopharma for up to $140 million in a bid to expand its pipeline of antimicrobial drugs and boost its R&D muscle in infectious disease.
This time next week, the Boston Convention and Exhibition Center will be positively buzzing with a broad range of those in the pharmaceutical industry for the annual DIA global meeting.
Coordinating with Migraine and Headache Awareness Month (MHAM), this June, Pfizer has announced it is partnering with multi-award winning, singer and actress, Lady Gaga, who was diagnosed with migraine when she was 14.
Multinational pharmaceutical company, Gedeon Richter UK Ltd, announced this week that it has acquired full marketing and distribution rights to a contraceptive range.
In a bid to address the high demand for clinical research talent, Advanced Clinical is hosting an innovation theater at DIA Global in Boston’s Convention and Exhibition Center.
The US Food and Drug Administration (FDA) has announced this month (June) it is requesting feedback on draft recommendations and how they should be applied to increasingly diverse trial types and data sources.
A cannabinoid receptor, that has shown potential as an effective treatment for chemotherapy induced peripheral neuropathy (CIPN) has been given approval for a phase 1 clinical trial by the Medicines and Healthcare Products Regulatory Agency (MRHA) and...
Global Healthcare Opportunities (GHO) Capital Partners LLP along with Partners Group has announced today (May 25) that it has invested an undisclosed amount in GHO portfolio company, Sterling Pharma Solutions.
A biotech advancing small molecule antibiotics through preclinical studies has closed its seed financing round of €1.2million ($1.3million) from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF).
Vicore Pharma’s drug candidate, C21 formulation, currently in a phase 2a trial aimed at people with idiopathic pulmonary fibrosis (IPF), has been patented.
Small molecule drug, Tagrisso (Osimertinib) taken alongside chemotherapy has showed a strong improvement in progression-free survival for patients with EGFR (epidermal growth factor receptor)-mutated advanced lung cancer, a phase 3 study has revealed.
With an increase in clinical studies demanding an increase in CRAs, we spoke to Sara Brannon, director of quality and training development, at ICON, to find out their approach to recruiting and how the industry is suffering due to a global shortage because...
A company says it is developing a small molecule drug without major safety issues to treat a growing number of cases of atrial fibrillation, the most common cardiac arrhythmia.
The company unveils the creation of the Institute of Human Biology, which will provide efficacy studies of drug candidates using miniature ‘living replicas’ of human tissues and organs.
The Japanese pharmaceutical giant Astellas Pharma has taken over the U.S. company Iveric Bio in a $5.9 billion deal to get hold of its ophthalmology-focused pipeline.
Only a few months after being bought out, the CDMO invests in its capabilities with a facility to support drug-device products and sterile fill-finish.
The German and Spanish companies use their relevant expertise in conjunction to provide clients with services spanning from hit generation to pre-clinical development.
Dutch biopharmaceutical company, Pharming Group PV, has sent its first commercial shipments of a drug to treat a rare, primary immunodeficiency, to the US.
The two French-based companies announced a strategic collaboration at the end of last month (March 2023) that saw Galapagos’ employees working in the research and discovery departments and transferred across to the contract research organization (CRO)....
The naloxone hydrochloride nasal spray will be made available over-the-counter, therefore not requiring a prescription, in an effort to reduce deaths from opioid abuse.
Medicine developer, CatSci Ltd announced yesterday (March 15) that it has formed a new partnership with AGC Pharma Chemicals, a small molecule Contract Development and Manufacturing Organisation (CDMO).